BioIncubator - our Pipeline

Our BioIncubator comprises promising R&D projects with high value creation potential. The developments are carried out in-house or together with industry partners. Current pipeline projects:

Deucrictibant as biopharmaceutical ingredient

The compound Deucrictibant (former name: PHA121) has been identified and characterized at our research site in Potsdam, Germany (AnalytiCon Discovery), and has been licensed to Pharvaris N.V. (Nasdaq: PHVS). The compound for the treatment of bradykinin-mediated diseases as HAE is currently in clinical development. 

Enzyme for wound healing

Aurase® is an enzymatic compound developed by BRAIN Biotech for the cleansing of chronic wounds. SolasCure Ltd., a company founded with the participation of BRAIN Biotech, is working on the registration of this medical compound. Initial clinical development has yielded promising data demonstrating the enzyme's great potential as a clinically effective means of debridement (removal of infected and non-viable tissue) and its safe application. The compound has successfully completed phase 2a clinical trials. SolasCure is currently preparing for phase 2b/3 clinical development and is in the process of financing further business activities.

Gold recovery from waste streams

Development of microorganisms and a bioprocess for the environmentally friendly recovery of gold: Upscaling process with industrial partner.

G-dase E®/G-dase M® enzymes for genome editing

These enzymes are proprietary CRISPR nucleases developed by BRAIN Biotech AG's Akribion Genomics team to build a genome editing technology platform. The development of G-dase E® is aimed, among other things, at a new type of cancer therapy. Both nucleases can also be used for gene editing in industrial biotechnology.